Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed to herald a new era in the management of type 2 diabetes (T2D), especially for the many patients with T2D who are at high risk for cardiovascular and renal events. However, as the evidence in favour of variou...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Diabetol
Main Authors: Schernthaner, Guntram, Shehadeh, Naim, Ametov, Alexander S., Bazarova, Anna V., Ebrahimi, Fahim, Fasching, Peter, Janež, Andrej, Kempler, Péter, Konrāde, Ilze, Lalić, Nebojša M., Mankovsky, Boris, Martinka, Emil, Rahelić, Dario, Serafinceanu, Cristian, Škrha, Jan, Tankova, Tsvetalina, Visockienė, Žydrūnė
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Commentary
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7585305/
https://ncbi.nlm.nih.gov/pubmed/33097060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01154-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados